- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03996538
Vaccination Efficacy With Metformin in Older Adults (VEME)
July 22, 2020 updated by: Jenna Bartley, UConn Health
Vaccination Efficacy With Metformin in Older Adults: A Pilot Study
With aging the immune system gets weaker.
This makes older adults more susceptible to influenza (flu).
Vaccinations help to prevent infection from the flu virus, however the immune system of older adults do not respond as well to vaccines compared to young adults and thus, aren't as well protected from the complications from the flu.
This research is being done to determine if Metformin, an FDA-approved diabetes medication, is effective at enhancing immune responses to flu vaccine in older men and women.
Participants will be randomly assigned to either metformin or placebo treatment for a total of 22 weeks.
Participants will be vaccinated with high-dose flu vaccine after 12 weeks of treatment.
Immune responses will be evaluated throughout the study at 6 time points.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- UCONN Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
63 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women 65 years and older
- Willingness to provide consent and participate in all aspects of the trial including randomization to the intervention group and receiving this year's flu vaccine
- Received previous year's seasonal influenza vaccine
Exclusion Criteria:
- History of severe renal impairment and/or eGFR ≤ 45 mL/min/1.73m2
- Excessive alcohol use (more than 14 alcoholic drinks/week) or clinical/laboratory evidence of hepatic disease (via medical history and/or AST and/or ALT ≥ 3 times upper limit of normal at screening)
- Acute or chronic metabolic acidosis (via medical history and/or low serum bicarbonate (< 22mEq/L), increased anion gap (> 10 mEq/L))
- History of B12 deficiency within the last 10 years
- Known type 2 diabetes or screening of prediabetic (HbA1c 5.7-6.4%) or diabetic (HbA1c ≥ 6.5%)
- Currently taking metformin or other diabetes medications
- Unwilling or unable (due to significant cognitive impairment) to provide informed consent
- Terminal illness with life expectancy less than 12 months
- Advanced neurological disorder (Parkinson's, ALS, MS, dementia)
- Cancer or history of cancer in the past 2 years (excluding non-melanoma skin cancer) or any history of metastatic (stage 4) cancer
- Significant co-morbid disease (severe chronic obstructive pulmonary disease, active rheumatologic diseases, chronic infection (HIV, tuberculosis), severe congestive heart failure (NYHA class 4), myocarditis, etc)
- Myocardial infarction, stroke or hospitalization for heart failure in the last 12 months
- Severe active psychiatric disorder (e.g. bipolar, schizophrenia)
- Unable to complete physical performance testing due to medical conditions (at discretion of the PI)
- Uncontrolled hypertension (systolic/diastolic blood pressure >150/90 mmHg)
- Unintentional weight loss >10% in past 12 months
- Allergy or history of adverse reaction to flu vaccine or any ingredients in flu vaccine, including eggs
- History of Guillain-Barre syndrome following vaccination
- Immunosuppressive disorders or taking immunosuppressive medications (including oral prednisone > 10mg/day)
- Current participation in another interventional study
- Refusal to receive flu vaccine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metformin Hydrochloride Extended Release Tablets
Patients will consume 3 tablets of 500mg metformin hydrochloride extended-release tablets daily (1500mg/day (after 3 week dose gradation)).
|
Subjects will ingest 1500mg/day of metformin hydrochloride extended release.
Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
Other Names:
All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
Other Names:
|
Placebo Comparator: Placebo
Patients will consume 3 identical placebo tablets (after similar 3 week dose gradation).
|
All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cell-mediated Flu Vaccine Responses - inducible Granzyme B
Time Frame: Prior to vaccination (week 12) and 5 weeks post vaccination (week 17)
|
Change in inducible Granzyme B levels in peripheral blood mononuclear cells (PBMCs) stimulated ex vivo with live flu virus will be compared between the metformin and placebo group.
|
Prior to vaccination (week 12) and 5 weeks post vaccination (week 17)
|
Change in Cell-mediated Flu Vaccine Responses - interferon(IFN)-γ/interleukin(IL)-10 ratio
Time Frame: Prior to vaccination (week 12) and 5 weeks post vaccination (week 17)
|
Change in interferon(IFN)-γ/interleukin(IL)-10 ratio in culture supernatant of peripheral blood mononuclear cells (PBMCs) stimulated ex vivo with live flu virus will be compared between the metformin and placebo group.
|
Prior to vaccination (week 12) and 5 weeks post vaccination (week 17)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Influenza Antibody Titers
Time Frame: Prior to treatment (week 0), prior to vaccination (week 12), and after vaccination (week 13, 17, and 22)
|
Serum antibody titers will be analyzed via hemagglutination inhibition assays (HI) via established Center for Disease Control (CDC) and World Health Organization (WHO) protocols for each vaccine strain.
Change in antibody titer levels over time will be evaluated.
|
Prior to treatment (week 0), prior to vaccination (week 12), and after vaccination (week 13, 17, and 22)
|
Change in T Cell Metabolic Phenotype
Time Frame: Prior to treatment (week 0), prior to vaccination (week 12), and after vaccination (week 13, 17, and 22)
|
T cells will be evaluated for phenotypic differences of glucose transporter expression via flow cytometry and reported as percent positive cells.
Change in percent positive cells over time will be evaluated.
|
Prior to treatment (week 0), prior to vaccination (week 12), and after vaccination (week 13, 17, and 22)
|
Change in T Cell Oxygen Consumption Rate
Time Frame: Prior to treatment (week 0), prior to vaccination (week 12), and after vaccination (week 13, 17, and 22)
|
T cells will be evaluated for oxygen consumption rate via Seahorse Agilent Technologies.
Change in oxygen consumption rate over time will be evaluated.
|
Prior to treatment (week 0), prior to vaccination (week 12), and after vaccination (week 13, 17, and 22)
|
Change in Frailty Phenotype
Time Frame: Prior to treatment (week 0), prior to vaccination (week 12), and after vaccination (week 13, 17, and 22)
|
Subjects will complete frailty testing via Fried Frailty Phenotype.
Change in frailty phenotype over time will be evaluated.
|
Prior to treatment (week 0), prior to vaccination (week 12), and after vaccination (week 13, 17, and 22)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jenna M Bartley, PhD, UCONN Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 5, 2019
Primary Completion (Actual)
February 4, 2020
Study Completion (Actual)
February 4, 2020
Study Registration Dates
First Submitted
June 19, 2019
First Submitted That Met QC Criteria
June 20, 2019
First Posted (Actual)
June 24, 2019
Study Record Updates
Last Update Posted (Actual)
July 23, 2020
Last Update Submitted That Met QC Criteria
July 22, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-205-2
- 18155 (AFAR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
Amazentis SAproDERM GmbHCompleted
-
Northumbria UniversityUniversity of East AngliaSuspendedSleep | Aging | Healthy AgingUnited Kingdom
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
Clinical Trials on Metformin Hydrochloride Extended-Release Tablets
-
Johns Hopkins UniversityBaylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple UniversityNot yet recruitingAsthma | Overweight and Obesity | Asthma Chronic
-
University of ArizonaNational Cancer Institute (NCI)RecruitingOral Leukoplakia | ErythroplakiaUnited States, Canada
-
National Cancer Institute (NCI)RecruitingLung CarcinomaUnited States, Canada
-
AstraZenecaRecruiting
-
AbbottRecruitingFunctional DyspepsiaMalaysia, Armenia
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Breast Ductal Carcinoma In Situ | Invasive Breast CarcinomaUnited States, Italy
-
IPCA Laboratories Ltd.Completed
-
Ranbaxy Laboratories LimitedCompleted
-
Ranbaxy Laboratories LimitedCompletedHealthyUnited States